Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Cowen and Company 36th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, Massachusetts from March 7-9, 2016. Ocera’s presentation will take place in Salon H on Monday, March 7th at 3:20 PM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
